Systemic scleroderma has high economic burden

Systemic scleroderma has high economic burden PharmacoEconomics & Outcomes News 792, p29 - 2 Dec 2017 Systemic scleroderma has high economic burden Systemic scleroderma (SSc) appears to be associated with a high economic burden due to unemployment and reduced work productivity, according to findings of the Australian Scleroderma Cohort Study published in Rheumatology. In this study conducted across four states of Australia between December 2007 and January 2016, 476 patients with systemic scleroderma completed four questionnaires: the Workers’ Productivity and Activity Impairment Questionnaire, a customised questionnaire on employment, the Medical Outcome Short Form 36-item (SF-36) health survey, and Patient-Reported Outcomes Measurement Information System 29 (PROMIS 29). Work-related costs for unemployment and lost productivity were estimated from a societal perspective. Only 55.2% of respondents under 65 years of age were employed. Those who were unemployed were older than patients with employment (57.1 vs 53.7 years; p<0.001) and had a longer disease duration (16.2 vs 14.9 years; p=0.01). The mean age at which patients became unemployed was 13.2 years below the average age of retirement in Australia. Among employed patients who worked during the previous week, 16.0% reported systemic scleroderma- related absenteeism totalling 32.9% of the working week, and reduced work productivity (presenteeism) accounted for 22% of the week. Estimated annual costs due to unemployment and reduced productivity totalled $67 595.40 per patient. Estimated annual costs for lost productivity in employed patients were $8024.20 per patient. "SSc is associated with considerable unemployment and reduced productivity, which in turn are associated ** with poor HRQoL and a substantial economic burden to employers and the wider society," concluded the investigators. * 2015 Australian dollars ** health-related quality of life Morrisroe K, et al. Work productivity in systemic sclerosis, its economic burden and association with health-related quality of life. Rheumatology : 9 Oct 2017. Available from: URL: 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792 PharmacoEconomics & Outcomes News Springer Journals

Systemic scleroderma has high economic burden

1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial